43 83

Cited 0 times in

Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy

DC Field Value Language
dc.contributor.author강창무-
dc.contributor.author김명진-
dc.contributor.author박미숙-
dc.contributor.author방승민-
dc.contributor.author성진실-
dc.contributor.author양현경-
dc.contributor.author정용은-
dc.contributor.author최진영-
dc.contributor.author한경화-
dc.date.accessioned2024-03-22T06:34:21Z-
dc.date.available2024-03-22T06:34:21Z-
dc.date.issued2024-01-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/198572-
dc.description.abstractPurpose Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).Conclusion “Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCA-19-9 Antigen-
dc.subject.MESHCarcinoma, Pancreatic Ductal* / surgery-
dc.subject.MESHHumans-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHPancreatic Neoplasms* / drug therapy-
dc.subject.MESHPancreatic Neoplasms* / surgery-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.titleRisk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorHyun Kyung Yang-
dc.contributor.googleauthorMi-Suk Park-
dc.contributor.googleauthorKyunghwa Han-
dc.contributor.googleauthorGeonsik Eom-
dc.contributor.googleauthorYong Eun Chung-
dc.contributor.googleauthorJin-Young Choi-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorChang Moo Kang-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorMyeong-Jin Kim-
dc.identifier.doi10.4143/crt.2023.586-
dc.contributor.localIdA00088-
dc.contributor.localIdA00426-
dc.contributor.localIdA01463-
dc.contributor.localIdA01786-
dc.contributor.localIdA01956-
dc.contributor.localIdA06172-
dc.contributor.localIdA03662-
dc.contributor.localIdA04200-
dc.contributor.localIdA04267-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid37605535-
dc.subject.keywordCA-19-9 antigen-
dc.subject.keywordNeoadjuvant therapy-
dc.subject.keywordPancreatic ductal carcinoma-
dc.subject.keywordPrognosis-
dc.subject.keywordX-ray computed tomography-
dc.contributor.alternativeNameKang, Chang Moo-
dc.contributor.affiliatedAuthor강창무-
dc.contributor.affiliatedAuthor김명진-
dc.contributor.affiliatedAuthor박미숙-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor양현경-
dc.contributor.affiliatedAuthor정용은-
dc.contributor.affiliatedAuthor최진영-
dc.contributor.affiliatedAuthor한경화-
dc.citation.volume56-
dc.citation.number1-
dc.citation.startPage247-
dc.citation.endPage258-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.56(1) : 247-258, 2024-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.